Asset profile
Solbinsiran
RNA / oligonucleotide
Evidence outlook · lead readout
PROLONG-ANG3 (NCT05256654) · Dyslipidemias, Lipid Metabolism Disorders, Metabolic Diseases, Hyperlipoproteinemia
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
PROLONG-ANG3 (NCT05256654): The study randomized 205 participants to three solbinsiran doses or placebo and masked both participants and investigators. Its primary endpoint was a laboratory biomarker rather than a hard clinical outcome, and the ApoB comparison was mixed across doses: significant for 400 mg but not for 100 mg or 800 mg, supporting moderate evidence rather than the highest grade.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
70 competitors in this universe: 9 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 62 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Solbinsiran: this drug | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| Evinacumab (Evkeeza) | Phase 3 | Monoclonal antibody | ANGPTL3 | ||
| ALN-ANG3 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| BW-00112 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| EDP167 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| HRS-7249 | Phase 2 | Unknown Undisclosed | ANGPTL3 | ||
| SYH2070 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | ||
| AZD1705 | Phase 1 | Small molecule | ANGPTL3 | ||
| CTX310 | Phase 1 | Gene therapy / editing | ANGPTL3 | ||
| NNC0491-6075 | Phase 1 | Unknown Undisclosed | ANGPTL3 | ||
| SHR-1918 | Phase 3 | Monoclonal antibody | ANGPTL3 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) |
…and 55 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
3 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
March 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.